WO2014157852A1 - Composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif - Google Patents

Composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif Download PDF

Info

Publication number
WO2014157852A1
WO2014157852A1 PCT/KR2014/001932 KR2014001932W WO2014157852A1 WO 2014157852 A1 WO2014157852 A1 WO 2014157852A1 KR 2014001932 W KR2014001932 W KR 2014001932W WO 2014157852 A1 WO2014157852 A1 WO 2014157852A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
release
sustained
active ingredient
weight
Prior art date
Application number
PCT/KR2014/001932
Other languages
English (en)
Korean (ko)
Inventor
김기운
이승후
정숙인
Original Assignee
초당약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 초당약품공업 주식회사 filed Critical 초당약품공업 주식회사
Publication of WO2014157852A1 publication Critical patent/WO2014157852A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a sustained release formulation composition containing eferison as an active ingredient. More particularly, the present invention relates to a sustained-release preparation composition containing erythrosone having hydroxypropylmethylcellulose (HPMC) and a release-controlling polymer added to an erythrosine pharmaceutical composition comprising erythrosone and an acidifying agent.
  • Eperisone pharmaceutical composition in the sustained-release preparation of the present invention is an eperisone pharmaceutical composition which is stable to storage and pH change of the acid added to the pericone, and the perison pharmaceutical composition is stably sustained to the pH change in the gastrointestinal tract.
  • a sustained release formulation composition capable of releasing an active ingredient.
  • Eperisone is a drug used in the treatment of stiff paralysis due to neuromuscular diseases including painful muscle spasms associated with musculoskeletal diseases by acting as a relaxant on musculoskeletal smooth muscle and vascular smooth muscle represented by the following formula (1): It is short and the product which takes 50-150mg of dose three times a day is marketed now.
  • Eperisone having such a chemical structure has a problem of pH stability because the piperidine ring can be easily opened in an alkaline environment.
  • the development of the eferisone composition has been in progress to improve the pH stability and storage stability, and in particular, the sustained-release pharmaceutical composition in which an acidic pH adjusting agent is added to the eferison has been disclosed.
  • Korea Patent Registration No. 10-1156054 'Stable Ephericone-containing sustained-release pharmaceutical composition' includes a specific type of acidifying agent such as carbomer, citric acid and the like to be formulated to a pH range of 5.6 or lower, so that the long-term storage stability of the preparation and the long term in the gastrointestinal tract Due to the characteristics of sustained-release preparations, eferison sustained-release pharmaceutical compositions that can inhibit the decomposition of the main ingredient without changing the dissolution properties in extreme environments such as pH change are disclosed.
  • the patent document includes an acidifying agent selected from an acidic pH adjusting agent or an excipient exhibiting a pH of 5.0 or less when suspended, dissolved, swelled or blended in water, and has an acidity when prepared with a 0.5% (W / V) aqueous solution.
  • an acidifying agent selected from an acidic pH adjusting agent or an excipient exhibiting a pH of 5.0 or less when suspended, dissolved, swelled or blended in water, and has an acidity when prepared with a 0.5% (W / V) aqueous solution.
  • a stable eferisone-containing sustained-release pharmaceutical composition having a pH of 0.5 to 5.6 is disclosed, and acidic pH regulators used herein include alginic acid, acetic acid, formic acid, adipic acid, edetic acid, fumaric acid, lactic acid, malic acid, maleic acid, At least one selected from the group consisting of palmitic acid, propionic acid, sorbic acid, stearic acid, tartaric acid, ascorbic acid, erythorbic acid, citric acid, oxalic acid, succinic acid, toluenesulfonic acid, methanesulfonic acid, nitric acid, hydrochloric acid, phosphoric acid and sulfuric acid It is starting.
  • acidic pH regulators used herein include alginic acid, acetic acid, formic acid, adipic acid, edetic acid, fumaric acid, lactic acid, malic acid, maleic acid, At least one selected from the group consisting of
  • the present inventors have applied D-glucaric acid and D-glucoascorbic acid to epherizone to improve the storage and pH stability of eferison in the 'ephericone pharmaceutical composition with improved storage and pH stability' filed as the same as the present application.
  • a patent application has been disclosed for an eperison pharmaceutical composition in which at least one acid selected from nicotinic acid or chlorogenic acid is added as an acidifying agent and polyvinylpyrrolidone is added as a binder to form a stable composition between the eferison and the acidifying agent.
  • epherisone is prepared to be taken in three doses per day, but in the case of non-steroidal anti-inflammatory drugs (NSAIDs) co-prescribed in combination with the eferison preparation, it is usually to be taken in two doses per day.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • the patient's compliance with medications tends to be lowered when co-prescribing a combination, and thus, there has been a further demand for the development of a sustained-release formulation of eperisone that can be taken twice daily.
  • the present inventors have added hydroxypropylmethylcellulose (HPMC) and a release-controlling polymer to the eferison pharmaceutical composition in which the acidifier and the polyvinylpyrrolidone binder have been added to the eferison already developed by the present inventors.
  • HPMC hydroxypropylmethylcellulose
  • the present invention has been completed by developing a sustained release formulation composition containing a.
  • the problem to be solved by the present invention is to develop a sustained-release formulation containing eferisone that has a sustained release properties that can be taken in a dose twice a day, the present inventors have added an acidifier and a binder to the eferison already developed
  • the present invention aims to develop a sustained-release formulation composition containing erypoxyson, in which hydroxypropylmethylcellulose (HPMC) and a release-controlling polymer are added to a lysone pharmaceutical composition.
  • HPMC hydroxypropylmethylcellulose
  • HPMC hydroxypropylmethylcellulose
  • the epherizone pharmaceutical composition having the storage and pH stability is 20 to 60% by weight of esperison or a pharmaceutically acceptable salt thereof; D-glucarboxylic acid, D-glucoascorbic acid, gluconic acid, D-glucuronic acid, gluconolactone, glucuronolactone, glutamic acid, itaconic acid, caffeic acid, glycyric acid, ethanesulfonic acid, benzenesulfonic acid, dehydro 1 to 30% by weight of at least one acidifying agent selected from ascorbic acid, salicylic acid, salicylic sulfonic acid, molar assets, nicotinic acid or chlorogenic acid; 0.5 to 8 wt% binder as binder; And 10 to 80% by weight of a diluent.
  • HPMC hydroxypropyl methyl cellulose
  • the release control polymer is characterized in that at least one selected from microcrystalline cellulose, starch, crospovidone, low-substituted hydroxypropyl cellulose, sodium starch glyconate, sodium croscarmellose, calcium carboxymethyl cellulose or magnesium aluminum silicate. .
  • the sustained-release preparation composition containing eferison as the active ingredient is 30 to 55% by weight of the total content within 60 minutes of the initial dissolution in a buffer of pH 1.2, 55 to 85% by weight within 3 hours, and 85% within 5 hours. It is characterized by eluting more than%.
  • another object of the present invention is to use the Ephericone pharmaceutical composition having the above storage and pH stability as the immediate release layer and the sustained release formulation composition containing Ephericone as the active ingredient as a sustained release layer of the epherisone in the form of a bilayer It is to provide a sustained-release tablet containing.
  • another object of the present invention is to provide an efferison complex combination comprising a non-steroidal anti-inflammatory drug (NSAID) in addition to the sustained-release preparation composition containing eferison as the active ingredient.
  • NSAID non-steroidal anti-inflammatory drug
  • the non-steroidal anti-inflammatory drugs are celecoxib, aceclofenac, diclofenac, ibuprofen, dexibuprofen, loxoprofen, zaltoprofen, ketoprofen, meloxycamp, naproxen, etodollac, nabu It is characterized in that at least one selected from meton, felbinac, nimesulide.
  • the effect of the present invention is to provide a sustained-release preparation containing eperisone that has a sustained release property, which can be taken in two doses per day, to an eperison pharmaceutical composition in which an acidifying agent and a polyvinylpyrrolidone binder are added to the eferison It is to provide a sustained release formulation composition containing hydroxypropyl methyl cellulose (HPMC) and the eferison to which the release controlling polymer is added as a release controlling agent.
  • HPMC hydroxypropyl methyl cellulose
  • the present invention is 50-90% by weight of the epherisone pharmaceutical composition with storage and pH stability; 1-20% by weight of hydroxypropylmethylcellulose (HPMC) as a release controlling agent; And 5 to 45% by weight of a release controlling polymer. It relates to a sustained-release preparation composition containing eferison as an active ingredient.
  • HPMC hydroxypropylmethylcellulose
  • the ephericone pharmaceutical composition in the sustained-release preparation is an eperisone pharmaceutical composition which is stable to storage and pH change of the acid added to the epherisone, and the eperison active ingredient is continuously stable to the pH change in the gastrointestinal tract. It relates to a sustained release formulation composition capable of releasing a drug.
  • Ephericone pharmaceutical compositions with storage and pH stability for use in the sustained release formulation compositions of the present invention comprise 20 to 60% by weight of epherisone or a pharmaceutically acceptable salt thereof; D-glucarboxylic acid, D-glucoascorbic acid, gluconic acid, D-glucuronic acid, gluconolactone, glucuronolactone, glutamic acid, itaconic acid, caffeic acid, glycyric acid, ethanesulfonic acid, benzenesulfonic acid, dehydro 1 to 30% by weight of at least one acidifying agent selected from ascorbic acid, salicylic acid, salicylic sulfonic acid, molar assets, nicotinic acid or chlorogenic acid; 0.5-8 wt.% Binder; And 10 to 80% by weight of a diluent.
  • the diluent used in the eferison pharmaceutical composition having the storage and pH stability may include at least one selected from microcrystalline cellulose, lactose hydrate, anhydrous lactose, starch, dextrose, sugar, maltitol, calcium hydrogen phosphate or mannitol.
  • At least one selected from D-glucuronic acid, gluconolactone, and glucuronolactone is preferable.
  • the content of the acidifying agent is an amount capable of adjusting the pH of the 1.0% (w / v) aqueous solution of the epherisone pharmaceutical composition to 2.0 to 5.5.
  • hydroxypropylmethylcellulose (HPMC) as a release control agent used in the sustained-release preparation composition of the present invention has a viscosity in the range of 6 to 10,000 cps. If the viscosity exceeds 10,000 cps, the dissolution of the drug is lowered.
  • the controlled release polymer used in the sustained-release preparation composition of the present invention is microcrystalline cellulose, starch, crospovidone, low-substituted hydroxypropyl cellulose, sodium starch glycolate, croscarmellose sodium, carboxymethyl cellulose calcium or magnesium aluminum silicate
  • At least one selected from the group and the release-controlling polymer can be used in combination with each other hydroxypropylmethylcellulose (HPMC) used as a release control agent to be able to more stably control the release of the efericone pharmaceutical composition with storage and pH stability .
  • HPMC hydroxypropylmethylcellulose
  • the active ingredient of the present invention is preferably in the form of hydrochloride, and the content of eferison hydrochloride contained in a single dose is preferably 75 to 150 mg.
  • the sustained-release preparation composition containing eferison as the active ingredient is 30 to 55% by weight of the total content within 60 minutes of the initial dissolution in a buffer of pH 1.2, 55 to 85% by weight within 3 hours, and 85% within 5 hours. It is characterized by eluting more than%.
  • another object of the present invention is to use the Ephericone pharmaceutical composition having the above storage and pH stability as the immediate release layer and the sustained release formulation composition containing Ephericone as the active ingredient as a sustained release layer of the epherisone in the form of a bilayer It is to provide a sustained-release tablet containing.
  • the rapid-release layer has the characteristic of eluting more than 85% by weight of the active ingredient within 60 minutes, and by taking the two-day dose more conveniently by preparing a sustained-release tablet containing eferisone in the form of a double layer by combining the two layers. Make it possible.
  • the present invention is to provide an anti-erythrone combination formulation including a non-steroidal anti-inflammatory analgesic (NSAID) in addition to the sustained-release preparation composition containing eferison as the active ingredient.
  • NSAID non-steroidal anti-inflammatory analgesic
  • Sustained-release formulation compositions containing eperisons of the present invention may additionally comprise non-steroidal anti-inflammatory drugs (NSAIDs), for example celecoxib, aceclofenac, diclofenac, ibuprofen, dexibuprofen, roxofero
  • NSAIDs non-steroidal anti-inflammatory drugs
  • aceclofenac diclofenac
  • ibuprofen ibuprofen
  • dexibuprofen roxofero
  • pen zaltoprofen
  • ketoprofen meloxycamp
  • naproxen etodolak
  • nabumethone felbinac and nimesulide
  • Concomitantly administering the sustained-release preparation composition containing eferisone, which can be taken in a twice daily dose of the present invention, and a non-steroidal anti-inflammatory drug, which is taken twice a day, further improves the patient's convenience and improves medication compliance. You can.
  • the sustained-release preparation composition containing the epherisone of the present invention can be prepared by mixing each of the composition components through a conventional direct method, a wet method, a dry method, and the like, as well as general granular bead pellet tablet capsule pills, as well as their multilayer tablets, It may be formulated in the form of coated tablets, nucleated tablets, or matrix.
  • ephericone hydrochloride 100 g of ephericone hydrochloride, 20 g of glucuronic acid as an acidifying agent, and 175 g of lactose hydrate as a diluent were quantified, and apples were added to a 24 mesh sieve and mixed for 5 minutes.
  • a binder 5 g of polyvinylpyrrolidone (PVP K30) was dissolved in 50 ml of isopropanol to form a binding solution, and then 300 g of eferison pharmaceutical composition was prepared from the mixture.
  • PVP K30 polyvinylpyrrolidone
  • the content of the sustained-release preparation containing ephericone as the final active ingredient was 75 mg of epherisone hydrochloride, 15 mg of glucuronic acid, 131.25 mg of lactose hydrate, 8.75 mg of polyvinylpyrrolidone, 36 mg of HPC, and 30 mg of microcrystalline cellulose. .
  • the preparation was carried out in the same manner as in Preparation Example 1, except that 30 g of low-substituted hydroxypropyl cellulose was used instead of 30 g of microcrystalline cellulose as the release controlling polymer.
  • the content of sustained-release preparations containing ephericone as the final active ingredient is 75 mg of epherisone hydrochloride, 15 mg of glucuronic acid, lactose hydrate 131.25 mg, polyvinylpyrrolidone 8.75 mg, HPMC 36 mg, low-substituted hydroxide It was 30 mg of oxypropyl cellulose.
  • Example 1 In Example 1 except that 30 g of sodium starch glycolate was used instead of 30 g of microcrystalline cellulose as the release-controlling polymer, it was prepared in the same manner as in Example 1.
  • the content of sustained-release preparations containing eferison as the final active ingredient is 75 mg of eferison hydrochloride, 15 mg of glucuronic acid, lactose hydrate 131.25 mg, polyvinylpyrrolidone 8.75 mg, HPMC 36 mg, sodium starch glycolate per tablet 30 mg.
  • Preparation Example 1 Instead of adding the HPMC added in Preparation Example 1 was prepared in the same manner as in Preparation Example 1 by increasing the content of the release control polymer microcrystalline cellulose to 66g instead of 30g.
  • the component content of the sustained-release preparation containing ephericone as the final active ingredient was 75 mg of eferison hydrochloride, 15 mg of glucuronic acid, 131.25 mg of lactose hydrate, 8.75 mg of polyvinylpyrrolidone, and 66 mg of microcrystalline cellulose per tablet.
  • Preparation Example 1 Instead of adding the release control polymer microcrystalline cellulose added in Preparation Example 1 was prepared in the same manner as in Preparation Example 1 by increasing the content of HMPC to 66g instead of 36g.
  • the content of the sustained-release preparation containing ephericone as the final active ingredient was 75 mg of eperisone hydrochloride, 15 mg of glucuronic acid, 131.25 mg of lactose hydrate, 8.75 mg of polyvinylpyrrolidone, and 66 mg of HPMC per tablet.
  • Preparation Example 1 An eperison pharmaceutical composition was prepared by adding 20 g of glucuronic acid used as an acidifying agent in step 1 to prepare the epherison pharmaceutical composition in step 1 and instead increasing the content of the diluent lactose hydrate to 195 g. 225 g of the obtained eferrizone pharmaceutical composition was added to Preparation Example 1 Step 2 to prepare the same method as Preparation Example 1.
  • the content of the sustained-release preparation containing ephericone as the final active ingredient was 75 mg of eferison hydrochloride, 146.25 mg of lactose hydrate, 8.75 mg of polyvinylpyrrolidone, 36 mg of HPMC, and 30 mg of microcrystalline cellulose per tablet.
  • the sustained-release preparation composition containing eferison prepared according to the method of the present invention showed a stable and constant dissolution pattern compared to the sustained-release preparation composition prepared by the Preparation Comparative Example.
  • the tablet does not completely disintegrate during the time of staying in the stomach as well as the time passing through the small intestine, and the drug is continuously contained in the tablet. Done. In other words, while remaining in the stomach, only a part of the active ingredient, epherisone, is released and the remaining amount is gradually released as it passes through the small intestine remaining in the disintegrated tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif, la composition contenant 50-90 % en poids d'une composition pharmaceutique d'épérisone ayant une conservabilité et une stabilité au pH ; 1-20 % en poids d'hydroxypropylméthylcellulose (HPMC) utilisé comme agent de libération contrôlée ; et 5-45 % en poids d'un polymère de libération contrôlée.
PCT/KR2014/001932 2013-03-29 2014-03-10 Composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif WO2014157852A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130034259A KR101497354B1 (ko) 2013-03-29 2013-03-29 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
KR10-2013-0034259 2013-03-29

Publications (1)

Publication Number Publication Date
WO2014157852A1 true WO2014157852A1 (fr) 2014-10-02

Family

ID=51624760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/001932 WO2014157852A1 (fr) 2013-03-29 2014-03-10 Composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif

Country Status (2)

Country Link
KR (1) KR101497354B1 (fr)
WO (1) WO2014157852A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044020A1 (fr) * 2016-08-29 2018-03-08 초당약품공업 주식회사 Procédé de préparation de microsphère à libération prolongée d'épérisone, et préparation composite de microsphère à libération prolongée d'épérisone et d'acéclofénac

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160105662A (ko) 2015-02-27 2016-09-07 대원제약주식회사 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
KR102254307B1 (ko) * 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103544A2 (fr) * 2009-03-09 2010-09-16 Dinesh Shantilal Patel Nouvelle composition à libération prolongée de composés choisis dans la classe des relaxants musculaires à action centrale
KR101156054B1 (ko) * 2011-09-05 2012-06-20 주식회사 네비팜 안정한 에페리손 함유 서방성 의약조성물
KR20120083276A (ko) * 2009-10-09 2012-07-25 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103544A2 (fr) * 2009-03-09 2010-09-16 Dinesh Shantilal Patel Nouvelle composition à libération prolongée de composés choisis dans la classe des relaxants musculaires à action centrale
KR20120083276A (ko) * 2009-10-09 2012-07-25 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR101156054B1 (ko) * 2011-09-05 2012-06-20 주식회사 네비팜 안정한 에페리손 함유 서방성 의약조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIVEKSARATHI, K. ET AL.: "Dosage Form Design and Evaluation of Eperisone Hydrochloride Matrix Film Coated Extended Release Tablets", INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 4, no. 2, 2012, pages 575 - 581 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044020A1 (fr) * 2016-08-29 2018-03-08 초당약품공업 주식회사 Procédé de préparation de microsphère à libération prolongée d'épérisone, et préparation composite de microsphère à libération prolongée d'épérisone et d'acéclofénac

Also Published As

Publication number Publication date
KR101497354B1 (ko) 2015-03-02
KR20140118412A (ko) 2014-10-08

Similar Documents

Publication Publication Date Title
WO2013058450A1 (fr) Composition médicale à base d'épérisone stabilisée, et préparation à libération prolongée contenant celle-ci
WO2019059557A2 (fr) Composition médicinale comprenant un inhibiteur de sglt-2 et un bloqueur du récepteur de l'angiotensine
WO2019108021A2 (fr) Composition pharmaceutique comprenant du tofacitinib
WO2018021772A1 (fr) Formulation ayant des caractéristiques améliorées de libération de médicament en fonction du ph, contenant de l'ésoméprazole ou un sel pharmaceutiquement acceptable de celui-ci
WO2016060365A1 (fr) Formulation de metformine à libération prolongée et procédé pour sa préparation
KR20180058644A (ko) 바레니클린 서방성 제제 및 이의 제조 방법
WO2014157852A1 (fr) Composition médicinale à libération prolongée contenant de l'épérisone en tant que principe actif
WO2020242413A1 (fr) Combinaison comprenant de l'alogliptine et de la metformine
WO2018062685A1 (fr) Composite formé d'une seule couche, comprenant du candésartan et de l'amlodipine
WO2016013795A1 (fr) Preparation a liberation prolongee
WO2021118026A1 (fr) Formulation de comprimé à noyau contenant un inhibiteur de la pompe à protons et du mosapride
WO2018124700A1 (fr) Nouvelle préparation contenant un dérivé de benzimidazole
WO2019066555A1 (fr) Composition pharmaceutique comprenant un comprimé sphéroïdal à unités multiples contenant de l'ésoméprazole et un sel de qualité pharmaceutique de celui-ci, et procédé de préparation de la composition pharmaceutique
WO2018143511A1 (fr) Comprimé oral triple à libération prolongée contenant de la prégabaline
WO2020017808A1 (fr) Comprimé à désintégration orale contenant de la nalfuron
WO2013032206A1 (fr) Composition orale à libération prolongée contenant du chlorhydrate d'itopride, et procédé de préparation associé
WO2021221288A1 (fr) Association médicamenteuse comprenant du mosapride et un inhibiteur de la pompe à protons
WO2014163215A1 (fr) Composition pharmaceutique ayant un goût amer masqué
WO2021157883A1 (fr) Agent de capsule dure comprenant un inhibiteur entérique de pompe à protons et une formulation de mosapride à libération prolongée
WO2013157841A1 (fr) Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci
WO2017116031A1 (fr) Composition pharmaceutique contenant du géfitinib, pouvant être administrée à des patients présentant une intolérance au lactose, et présentant une commodité de dosage améliorée
WO2016137266A2 (fr) Composition pharmaceutique contenant de l'épérisone et du pélubiprofène
WO2021112548A1 (fr) Composition pharmaceutique
WO2014157851A1 (fr) Composition pharmaceutique d'épérisone ayant une conservabilité et une stabilité au ph améliorées
WO2015056956A1 (fr) Composition pharmaceutique à libération contrôlée à base d'acide propionique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14775958

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14775958

Country of ref document: EP

Kind code of ref document: A1